The H3K27 methyltransferase EZH2 has been reported to inhibit PD-L1 expression in HCC by promoting the H3K27me3 modification in the promoters of CD274, which encodes PD-L1, and the interferon regulatory factor 1 (IRF1) gene [164]. Here, EZH2 is linked to hepatocellular carcinoma.